ArticleEuropean journal of heart failure2021

The sodium-glucose co-transporter 2 inhibitor dapagliflozin improves prognosis in systolic heart failure independent of the obesity paradox.

Salvatore Carbone et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.